Sign In
Buy SMMT
$15.07
+0.210 (+1.41%)
At Close: Jun 03, 2026
Is SMMT Stock A Buy After Its Recent Plunge?
09:10am, Monday, 02'nd Jun 2025
Summit Therapeutics (NASDAQ: SMMT) experienced a significant 30% decrease in its stock on Friday, May 30th, closing at $18. This sudden decline came even though the stock had doubled within the past y
3 No-Brainer Healthcare Stocks to Buy in June
07:00am, Monday, 02'nd Jun 2025
A new month has arrived. Investors now have a fresh opportunity to buy great stocks.
Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy?
05:23am, Monday, 02'nd Jun 2025
Shares of Summit Therapeutics (SMMT -30.39%) tanked more than 30% on Friday, May 30. Such dramatic price swings aren't unusual in the biotechnology industry; in this case, disappointing data from an i
Summit Therapeutics: Moving Stock To 'Hold' Rating After Phase 3 HARMONi Data Release
02:50pm, Friday, 30'th May 2025
PFS in Phase 3 HARMONi study, using ivonescimab + chemotherapy to treat patients with EGFR 2nd-line NSCLC, was met with statistical significance, but OS was not. OS data not being met in a statistical
Why Summit Therapeutics Plunged Today
02:19pm, Friday, 30'th May 2025
Shares of Summit Therapeutics (SMMT -27.85%) have plunged 31% as of 1:23 p.m. ET Friday, following the release of some trial data this morning.
Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.
09:27am, Friday, 30'th May 2025
The trial was meant to answer the biggest question in biotech: What happens when U.S. companies test promising new Chinese cancer immunotherapies in western countries?
Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint
09:01am, Friday, 30'th May 2025
Summit Therapeutics Inc. SMMT released topline results on Friday from the Phase 3 HARMONi trial of ivonescimab plus platinum-doublet chemotherapy compared to placebo plus platinum-doublet chemotherap
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced topline results from the Phase III clinical trial, HARMONi, the
Does Summit Therapeutics (SMMT) Have the Potential to Rally 44.6% as Wall Street Analysts Expect?
11:01am, Monday, 26'th May 2025
The mean of analysts' price targets for Summit Therapeutics (SMMT) points to a 44.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am
3 High-Flying Stocks That Could Soar Even More
06:40am, Saturday, 24'th May 2025
Many investors love the "big mo." That's short for "big momentum.
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
04:48am, Wednesday, 21'st May 2025
Resilient and growing. Those two descriptions definitely apply to the healthcare sector.
Got $100? 3 Top Growth Stocks to Buy That Could Double Your Money
05:47am, Sunday, 18'th May 2025
Everyone knows that it takes money to make money. However, you don't need much money to begin making money.
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 16'th May 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of
Wall Street Analysts Predict a 33.4% Upside in Summit Therapeutics (SMMT): Here's What You Should Know
11:00am, Tuesday, 06'th May 2025
The consensus price target hints at a 33.4% upside potential for Summit Therapeutics (SMMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin
Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil
10:05am, Friday, 02'nd May 2025
SMMT's first-quarter earnings outpace estimates. The company also provides updates on its pipeline.
